FRANKLIN, Tenn.--(BUSINESS WIRE)--A zero-displacement intravenous (IV) needleless connector was associated with dramatically lower infection rates when compared to positive- and negative- pressure connectors, a new, multisite study reports.
The study’s statistically significant data on IV connectors (also called hubs, valves and injection caps) was reported from five intensive care units and one long-term acute care (LTAC) facility.
After switching to the zero-displacement connector (InVision-Plus®, RyMed Technologies), participating facilities saw an overall reduction of approximately 75% in central-line associated bloodstream infection (CLABSIs).
Researchers also concluded the zero-displacement connector would result in substantial costs savings, and they estimated that use of the connector saved 13 lives.
The reduction in CLABSI rates was reported in the peer-reviewed journal, American Journal of Infection Control (AJIC). Similar data was the subject of a poster presentation at the recent 2nd International Conference on Prevention and Infection Control 2013 (ICPIC 2013).
“This long-term study is yet more evidence that IV connector design matters when it comes to preventing CLABSIs,” said Dr. Cynthia C. Chernecky, R.N., Ph.D., one of the study authors. “Our results show this connector has demonstrated much better ability to reduce infections in clinical settings, when compared to several positive- and negative-pressure connectors.”
Preventing CLABSIs is a major medical concern because the Centers for Disease Control and Prevention (CDC) has estimated that U.S. patients suffer approximately 250,000 such infections each year. CLABSIs have an estimated mortality rate of 12% to 25%, according to the CDC, and cost an average of $35,000 to treat.
One of the study authors is William R. Jarvis, M.D., one of the nation’s leading experts on infection control. Dr. Jarvis was among the first researchers to call attention to the higher CLABSI risk associated with both positive- and negative-pressure IV connectors.
“It’s very important for clinicians to do research and publish their results about IV connectors,” Dr. Jarvis said. “This study adds important new information to what is known about the efficacy of various kinds of connectors.”
Compared to positive-pressure connectors, use of the zero-displacement connector reduced infections by approximately 60%.
In the LTAC, InVision-Plus was compared to two negative-pressure connectors: a split septum connector and a mechanical valve device. The zero-displacement device (InVision-Plus) reduced CLABSIs by approximately 94%.
Overall, the study encompassed 70 months and more than 70,000 catheter days.
The AJIC article also projected substantial financial savings when the six facilities switched from a positive or negative pressure connector to InVision-Plus. Because of avoided CLABSIs, the facilities saved a projected $3 million in infection treatment costs, the researchers said.
Other authors on the study and poster were Denise Macklin B.S.N., R.N.C, VA-BC, and Thomas V. Joshua, M.S.
The text of the ICPIC poster was also published on the website of the journal Antimicrobial Resistance and Infection Control. The ICPIC 2013 conference was held June 25-28 in Geneva, Switzerland.
* Study of cancer patients comparing zero-displacement IV needleless connector (InVision-Plus) to negative-pressure, split-septum connector
* Article by Sophie Harnage, RN, BSN, VA-BC, of Sutter Roseville Medical Center’s central line bundle. Sutter has gone more than seven and one half years without a BSI.
* Article by William Jarvis, M.D., on design features of IV needleless connectors that are important for preventing CRBSIs
About RyMed Technologies, Inc.
Founded in 1994, RyMed Technologies, Inc. specializes in innovative safety products in the field of intravenous catheter care management. The company's products are designed to help reduce catheter occlusions, central-line associated bloodstream infections (CLABSIs), and biofilm development commonly associated with vascular access devices. More than 10 years of research and development have gone into the InVision-Plus product line. Numerous studies regarding the efficacy of the InVision-Plus Needleless IV Connector have been published -- which is particularly important in light of the growing incidence of CRBSIs.
The company is headquartered in Franklin, Tenn. For more information, access www.rymedtech.com or call (615) 790-8093.